{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:14:20Z","timestamp":1758892460819,"version":"3.40.4"},"reference-count":47,"publisher":"S. Karger AG","issue":"11-12","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2021]]},"abstract":"<b><i>Introduction:<\/i><\/b> The effect of icotinib on non-small cell lung cancer (NSCLC) patients with <i>EGFR<\/i> exon 19 deletions (19-Del) or L858R point mutation in exon 21 (21-L858R) remains inconsistent. This study aimed to evaluate the efficacy and safety of icotinib in patients with advanced NSCLC harboring these 2 <i>EGFR<\/i> mutations. <b><i>Methods:<\/i><\/b> We retrospectively assessed the clinical effects of first-line icotinib on advanced NSCLC patients with 2 classic <i>EGFR<\/i> mutations. Kinase activity assays were used to reaffirm the preclinical efficacy. <b><i>Results:<\/i><\/b> Among 2,757 patients, 2,365 (86%) harbored 19-Del (1,346\/2,757, 49%) or 21-L858R (1,019\/2,757, 37%) mutation. Patients with 19-Del had a higher response rate (ORR; 67.8 vs. 62.1%; <i>p<\/i> = 0.0039) and disease control rate (98.5 vs. 97.2%; <i>p<\/i> = 0.0223) than those with 21-L858R mutation. The median progression-free survival (PFS) in the 19-Del group (22.3 months, 95% confidence interval [CI]: 21.3\u201323.4) was significantly longer than that in the 21-L858R group (20.4 months, 95% CI: 19.5\u201321.7) (<i>p<\/i> = 0.004). In multivariate analysis, mutation types, clinical stage, and smoking history were significant factors for PFS. Additionally, an in vitro study indicated the 50% inhibitory concentrations (IC<sub>50<\/sub>) of icotinib was lower for <i>EGFR<\/i> 19-Del than 21-L858R. <b><i>Conclusion:<\/i><\/b> These results suggest that <i>EGFR<\/i> 19-Del confers superior PFS and response to the icotinib treatment compared to 21-L858R. <\/jats:p>","DOI":"10.1159\/000519847","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T21:01:16Z","timestamp":1634850076000},"page":"658-666","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China"],"prefix":"10.1159","volume":"106","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangbo","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20102"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3741"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq742"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1154"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.198"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2088"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2010.03.002"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S108242"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1515\/med-2016-0003"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S97100"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0462"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S138643"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70381-X"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3064"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70355-3"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx359"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12085"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S98363"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.956"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30035-X"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61758-4"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70385-0"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000033"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24746"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv270"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0462"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.11.037"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.1736"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S93823"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095897"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.11.007"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.10.023"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-013-9715-0"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31829f684a"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2012.05.09"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji238"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.07.030"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1102"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70310-3"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603564"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/519847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/519847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:29:12Z","timestamp":1745422152000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000519847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":47,"journal-issue":{"issue":"11-12","published-online":{"date-parts":[[2021,11,9]]},"published-print":{"date-parts":[[2021,11,16]]}},"URL":"https:\/\/doi.org\/10.1159\/000519847","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"type":"print","value":"0031-7012"},{"type":"electronic","value":"1423-0313"}],"subject":[],"published":{"date-parts":[[2021]]}}}